Continuing Education Information
© 2015 Harborside Press®
ARTICLE
Methotrexate and Fluorouracil Toxicities:
What Advanced Practitioners in Oncology Need to Know
A continuing education activity for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians
Release date: March 15, 2015
Expiration date: March 15, 2016
Estimated time to complete this activity: 1.00 hours
This activity is supported by an unrestricted educational grant from BTG International.
© 2015, Meniscus Educational Institute. All rights reserved.
Faculty
Christopher J. Campen, PharmD, BCPS, BCOP, Arizona Cancer Center, University of Arizona
Wendy H. Vogel, MSN, FNP, AOCNP®, Wellmont Cancer Institute
Julie M. Vose, MD, MBA, University of Nebraska Medical Center
Activity Rationale and Purpose
The journal supplement will focus on the prevention and management of methotrexate and fluorouracil-related toxicities, especially with regard to proper dosing, the current standard of care, collaborative models of assessment and monitoring, and continued high levels of supportive care. The supplement will also cover expanded access programs, including their purpose, benefits, and potential concerns. The goal is to provide the tools healthcare professionals need to expand delivery of state-of-the-art medical care, improve patient outcomes, and enhance the quality of life in patients with cancer, as well as reduce the barriers impacting the integration of therapies into practice and support adherence to current guidelines.
Intended Audience
The activity’s target audience will consist of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Learning Objectives
After completing this educational activity, participants should be able to:
- Summarize the effects of methotrexate (MTX)- and fluorouracil (5-FU)–induced toxicities on managing cancer
- Describe the appropriate strategies for managing MTX- and 5-FU–induced toxicities
- Discuss collaborative practice initiatives for managing MTX- and 5-FU–induced toxicities
- Become familiar with the clinical considerations regarding the use of glucarpidase for MTX toxicity and uridine triacetate for 5-FU overexposure
- Review the most recent FDA guidelines on expanded access programs and their effect on clinical practice
Continuing Education
Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.
Physicians. The Meniscus Educational Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Meniscus Educational Institute designates this journal article (271.012.1503-MJ) for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. This activity (271.012-1503-NJ) for 1.00 contact hours is provided by the Meniscus Educational Institute.
The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 1.00 contact hours.
Pharmacists. The knowledge-based accredited education lectures are intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Meniscus Educational Institute.
The Meniscus Educational Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to this program, for 1.00 contact hours, is 0429-9999-15-003-H01-P.
Financial Disclosures
All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Meniscus Educational Institute has identified and resolved all conflicts of interest in accordance with the MEI policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
|
Planners Christopher J. Campen, PharmD, BCPS, BCOP, has owned stock from AbbVie. Jeannine Coronna has nothing to disclose. Joseph Cupolo has nothing to disclose. Claudine Kiffer has nothing to disclose. Terry Logan, CHCP, has nothing to disclose. Susan Reckling has nothing to disclose. Molly Thompson has nothing to disclose. Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose. Wendy H. Vogel, MSN, FNP, AOCNP®, has been a part of speakers bureaus for Novartis, Celgene, Genentech, Lilly, Onyx/Bayer, and Regeneron/Sanofi. Julie M. Vose, MD, MBA, has received research funding from Allos Therapeutics/Spectrum, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Incyte, Janssen Biotech, Pharmacyclics, and US Biotest. Lead Nurse Planner Rita Wickham, PhD, RN, AOCN®, has received honoraria from Genentech. |
Faculty Christopher J. Campen, PharmD, BCPS, BCOP, Wendy H. Vogel, MSN, FNP, AOCNP®, has been a part of speakers bureaus for Novartis, Celgene, Genentech, Lilly, Onyx/Bayer, and Regeneron/Sanofi. Julie M. Vose, MD, MBA, has received research funding from Allos Therapeutics/Spectrum, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Incyte, Janssen Biotech, Pharmacyclics, and US Biotest. WRITERS Joseph Cupolo has nothing to disclose. Susan Reckling has nothing to disclose. Content Reviewers Margaret M. Fields, RN, ACNP-BC, AOCNP®, has nothing to disclose. Claudine Kiffer has nothing to disclose. Allison Muller, PharmD, has nothing to disclose. Moshe Ornstein, MD, MA, has nothing to disclose. |
Disclaimer
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Meniscus Educational Institute educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.
Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment and complete and submit the evaluation form with an E-mail address) will be able to download a statement of credit.